Experience in Spain with the first patients in home hemodialysis treated with low-flow dialysate monitors.

Autor:	Roblero MFS; Complejo Hospitalario Navarra, IdiSNA, Navarra, Spain. Electronic address: mf.slon.roblero@navarra.es., Rubio MAB; Hospital Universitario La Paz, Madrid, IdiPAZ, Madrid, Spain., González-Moya M; Hospital Universitari Dr. Peset, FISABIO, Valencia, Spain., Varela JC; Hospital Lucus Augusti, Lugo, Spain., Alba AP; Hospital General de Castellón, Castellón, Spain., Gumpert JV; Hospital General de Valencia, Valencia, Spain., Cigarrán S; Hospital da Costa, Burela, Spain., Vidau P; Hospital Universitario Central de Asturias, Oviedo, Spain., Marcos SG; Hospital de Poniente, Almería, Spain., Luquin PA; Hospital Universitario de Burgos, Burgos, Spain., Piera EC; Fundacio Puigvert, Barcelona, Spain., Mariño AG; Hospital Obispo Polanco de Teruel, Teruel, Spain., Espigares MJ; Hospital Virgen de las Nieves, Granada, Spain., Molina MD; Departamento de Matemáticas, Universidad de Alicante, San Vicente del Raspeig, Alicante, Spain., Molina P; Hospital Universitari Dr Peset, FISABIO, Departamento de Medicina, Universitat de València, Valencia, Spain.
Jazyk:	angličtina
Zdroj:	Nefrologia [Nefrologia (Engl Ed)] 2022 Jul-Aug; Vol. 42 (4), pp. 460-470. Date of Electronic Publication: 2022 Nov 15.
DOI:	10.1016/j.nefroe.2022.11.004
Abstrakt:	Home hemodialysis (HHD) with low-flow dialysate devices has gained popularity in recent years due to its simple design, portability, and ability to provide greater freedom of movement for our patients. However, there are doubts about the adequacy that this technology offers, since it uses monitors with low-flow bath and lactate. The aim of this study was to demonstrate the clinical benefits of low-flow HHD with the NxStage System One® recently introduced in Spain. We present the results of an observational, retrospective cohort study that included the first patients who started short daily HHD with this device in 12 Spanish centers. We analyzed the evolution of 86 patients at 0, 6 and 12 months, including data related to prescription, and evolution of biochemical parameters related to dialysis dose, anemia, mineral-bone metabolism; evolution of residual renal function, medication usage, and causes of withdrawal during the followup. We were able to demonstrate that this NxStage System One® monitor, in patients with HHD, have provided an adequate dialysis dose, with optimal ultrafiltration rate, with improvement of main biochemical markers of dialysis adequacy. The usage of this technique was associated to a decrease of antihypertensive drugs, phosphate binders and erythropoietin agents, with very good results both patient and technique survival. The simplicity of the technique, together with its good clinical outcomes, should facilitate the growth and utilization of HHD, both in incident and prevalent patients. (Copyright © 2021 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu